Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Update on malignant hemopathies].

Valérie Ugo1, Ollivier Legrand, Alain Delmer

  • 1Département d'hématologie et d'oncologie médicale, Hôtel-Dieu, 75181 Paris Cedex 04 et Inserm EMI9912/EA1529, Paris 6.

Bulletin Du Cancer
|February 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms.

Annals of hematology·2026
Same author

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

EClinicalMedicine·2026
Same author

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Leukemia·2025
Same author

A specific bone marrow cytokine pattern in de novo acute myeloid leukemia.

Clinical immunology (Orlando, Fla.)·2025
Same author

A molecular signature predicts hematologic evolution in polycythemia vera patients.

Leukemia·2025
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

Molecular biology tools and targeted therapies like STI571 revolutionize cancer prognosis and treatment. These advancements, including monoclonal antibodies, offer new hope but come with significant costs.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Context:

  • The early 21st century witnessed two major shifts in cancer treatment.
  • The integration of molecular biology tools for enhanced disease prognosis.
  • The emergence of targeted therapies, or "intelligent" molecules, directed at cancer cells.

Purpose:

  • To highlight the impact of molecular biology and targeted therapies in hematology and oncology.
  • To discuss specific examples of these advancements and their implications.

Summary:

  • Routine use of molecular diagnostics (e.g., FLT3 in AML, Ig gene mutations in CLL, gene expression profiling in lymphomas) improves disease prognosis.
  • Discovery of targeted therapies like STI571 (Gleevec) for bcr-abl positive leukemias (CML, Ph1+ ALL).

Related Experiment Videos

  • Development of signal transduction inhibitors and therapeutic monoclonal antibodies (e.g., rituximab) for lymphoid malignancies and autoimmune diseases.

    • Impact:

    • These novel therapies offer improved treatment outcomes and patient management strategies.
    • The high cost of these advanced treatments presents a significant financial challenge for healthcare systems.
    • Monoclonal antibodies like rituximab demonstrate versatility, efficacy, and good tolerance, enabling outpatient use and combination therapies.